chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Breathing declined; Increased Blood Pressure; Headache; Fatigue; Fever of 103.3 degrees Fahrenheit; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 30-Mar-2021 and was forwarded to Moderna on 30-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (Breathing declined), HYPERTENSION (Increased Blood Pressure), HEADACHE (Headache), FATIGUE (Fatigue) and PYREXIA (Fever of 103.3 degrees Fahrenheit) in a 61-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 002A21A) for COVID-19 vaccination.     Concurrent medical conditions included AFib.    On 03-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Mar-2021, the patient experienced DYSPNOEA (Breathing declined), HYPERTENSION (Increased Blood Pressure), HEADACHE (Headache), FATIGUE (Fatigue) and PYREXIA (Fever of 103.3 degrees Fahrenheit). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) on 03-Mar-2021 at an unspecified dose and frequency. On 05-Mar-2021, DYSPNOEA (Breathing declined), HYPERTENSION (Increased Blood Pressure), HEADACHE (Headache), FATIGUE (Fatigue) and PYREXIA (Fever of 103.3 degrees Fahrenheit) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 03-Mar-2021, Blood pressure measurement: High. On 03-Mar-2021, Pyrexia: 103.3 (High) 103.3.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.
This spontaneous report as received from a healthcare worker refers to a 8 week old patient of unknown gender. The patient's relevant medical history, current conditions and concomitant medications were not reported. On 01-OCT-2015 the patient was vaccinated with improperly stored ROTATEQ (dosing details were not reported) lot # L008053, with an expiry date of 30-NOV-2016, orally. The vaccine was administered at public health clinic or hospital with public funds. No adverse effects were reported. There was no product quality complaint involved. This is one of the several reports received from the same reporter. Additional information has been requested.
PATIENT HAD ALLERGIC REACTION TO LATEX. RIGHT NOW PATIENT HAS BIG BUMP AND TAKING BENADRYL BUT IF IT GET WORSE THEN WILL SEE DOCTOR.
Patient received a Comirnaty Pfizer vaccine on 11/1/23.  She presented with vomiting and was taken to ER.  Nursing home health care provider said that she has other medical conditions as well.
This spontaneous report as received from a medical assistant refers to a 18 year old patient of unknown gender. The patient's drug allergies and pertinent medical history was not reported. On 02-JUL-2014 the patient was vaccinated with first dose of VAQTA (dose, frequency and route of administration were not reported) (lot # J005010, expiry date: 23-OCT-2014) which was stored improperly. No adverse effects were noted. No product quality complaint was reported for VAQTA. Addtional information has been requested.
nausea; This spontaneous case was reported by a consumer and describes the occurrence of NAUSEA (nausea) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011A21A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced NAUSEA (nausea). At the time of the report, NAUSEA (nausea) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No relevant concomitant medications were reported. No treatment information was provided.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
Information has been received from a third party claims administrator on behalf of a pharmacy concerning a female patient. On an unspecified date the patient was vaccinated with PNEUMOVAX 23 (lot # J004747, expiration date 20JUL2014). On an unknown date the patient experienced an adverse reaction (NOS). The outcome of the adverse reaction was unknown. Additional information has been requested.
She had an anaphylactic shock and almost died at the hospital; allergic reaction to the Pfizer; She had an anaphylactic shock and almost died at the hospital; allergic reaction to the Pfizer; This is a spontaneous report from a contactable consumer. A female patient of an unspecified age received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection), via an unspecified route of administration on an unspecified date (batch/lot number was not reported) as single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient previously received first dose of bnt16b2 on an unspecified date for COVID-19 immunization. The patient had an anaphylactic shock and almost died at the hospital; (allergic reaction to the Pfizer (vaccine)) on an unspecified date. The patient was hospitalized on unspecified date. Outcome of the events was unknown.   Information on the lot/batch number has been requested.
Had a mild rash on the day of immunization administration on 06/24/04. On 7/3/04 and 7/4/04 developed a fever up to 101. On 7/7/04 has a papular rash of the trunk spreading to extremities.
My menstrual cycle started early. Today my period started 12 days early, 2 days after receiving my second dose of the Pfizer COVID vaccine. After the first dose on February 16, my period started one week after the dose which was about 14 days early. I am super regular and now after both doses I have started my period early so I am concerned it?s related to the vaccine.
Erythema, swelling, warmth started at injection site (Left ant thigh)within 1 hour of injection. Radiated down left leg into foot during course of the day until about 2:00AM. Swelling & redness was significant. Child crying inconsolably. No fever. Wouldn't nurse. Dr. advised cool compresses to leg, bath and acetaminophen. Mother sent pictures of leg via cell phone.
No additional adverse events reported; an expired dose of ROTATEQ was administered; This spontaneous report was received from a registered nurse and refers to a 2 month old patient of unknown gender.    The patient's concurrent conditions, medical history, drug reactions, allergies and concomitant therapies were not provided.   On 11-NOV-2020 (also reported as yesterday), the patient was vaccinated with rotavirus vaccine, live, oral, pentavalent (ROTATEQ) orally (dose and frequency not reported) lot # S000954 has been verified to be a valid lot number, expiration date 17-OCT-2020 (expired product administered). It was reported that the vaccine was stored at the appropriate storage condition specified in the product label. No adverse event reported.
Rash at injection sight. About the size of my palm, began 5 days after shot is fading now, 03/15
Oral dysaesthesia - scratchy throat morning after vaccination, then developed tongue burning and progresses to full mouth Fatigue, headache, body aches
Day after-slight body aches,chest tightness  9/7/21 -   Patient continues to have shortness of breath, cough
Collapsed; Unable to walk on her own; Muscle pain; Nausea; Vomiting; Headache at the base of her head and neck; A spontaneous report was received from a consumer concerning a 72-year-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced the events, collapsed, unable to walk on her own, muscle pain, nausea, vomiting, and headache at the base of her head and neck.   The patient's medical history, as provided by the reporter, included stroke.  No relevant concomitant medications were reported.  On 30 Dec 2020, the patient received their first of two planned doses of mRNA-1273 (Lot Number: 026L20A)  in the left deltoid for prophylaxis of COVID-19 infection.   On 30 Dec 2020, after vaccine administration, the patient experienced a headache at the base of her head and neck.  On 03 Jan 2021, the patient collapsed and was unable to walk on her own.  She was hospitalized from 04 Jan 2021 to 05 Jan 2021. She also experienced muscle pain, nausea, and vomiting. No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of the events, collapsed, unable to walk on her own, muscle pain, nausea, vomiting, and headache at the base of her head and neck, was unknown.; Reporter's Comments: This case concerns a 72 year old, female patient with a history of stroke, who experienced a serious unexpected event of fall, gait inability and non-serious expected event of myalgia, nausea, vomiting and headache. The event of headache occurred same day after first dose mRNA-1273 (Lot# 026L20A) administration. The event of fall and gait inability occurred 5 days after first dose of mRNA-1273. The event of myalgia, nausea, vomiting occurred on an unspecified date after mRNA-1273 (Lot# 026L20A) administration. The treatment medications were not provided. Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.
THERE WAS AN ERROR IN ADMINISTRATION.  NO  DILUENT, RESULTING IN HIGHTER THAN AUTHORIZED DOSE ( 0.3ML  OF UNDILUTED VACCINE ADMINISTERED. )  ADVERSE EFFECTS INCLUDED FEVER, CHILLS AND MUSCLE ACHES THAT STARTED THE EVENING OF 10/26/21 THROUGH THE NIGHT.    MOTRIN AND ELECTROLYES TAKEN PER PATIENT AND FEELING BETTER ON 10/27/21 BY 1200 PM.    THIS WAS THE SAME REACTION SHE HAD TO THE FIRST DOSE OF PFIZER VACCINATION.
Unexplained fainting at approximately 9:00 pm on 5/20/2021; unexplained persistent bruising possibly indicative of low platelet count, first noticed on 5/22/21 at approximately 4:00 pm and continuing to the present
Vaccine exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) in a 33-year-old female patient (gravida 4, para 1) who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025A21A) for COVID-19 vaccination.     The patient's past medical history included Miscarriage on 26-May-2017, Miscarriage on 15-Nov-2017, Depression, Anxiety, Degenerative disc disease in 2009, Stenosis in 2009, Spinal osteoarthritis in 2009, Alcohol use from 2003 to 2011 and Ex-smoker from 2006 to 2020. Concurrent medical conditions included Allergy to topical drugs (allergic to sulfa drugs) and Latex allergy. Concomitant products included VALACICLOVIR HYDROCHLORIDE (VALTREX) and VALACICLOVIR HYDROCHLORIDE (VALTREX) for Cold sores, MAGNESIUM for Headache and Constipation, MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) for Pregnancy, ALCOHOL, NICOTINE and MARIJUANA.    On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on 02-Sep-2020 and the estimated date of delivery was 09-Jun-2021. On 25-Feb-2021, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  twenty-fifth week of the pregnancy.  On 25-Feb-2021, MATERNAL EXPOSURE DURING PREGNANCY (Vaccine exposure during pregnancy) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 27-Sep-2020, Pregnancy test: positive (Positive) Positive. On 27-Sep-2020, Ultrasound antenatal screen: normal (normal) normal.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   On a unknown dates, the patient reports having an ultrasound, NIPP, and genetic screening that resulted in normal findings.
13 days after vaccine, onset of serious symptoms occurred. Difficulty breathing, shortness of breath, coughing up bloody sputum, pain with breathing.  3 dys later, I was hospitalized , diagnosed and treated for a pulmonary embolism.
Other complications following immunization, not elsewhere classified, initial encounter on 2023-05-30.
NUMBNESS IN FINGER TIPS NUMBNESS IN HANDS TREATED WITH HAND BRACE WITH NO CHANGE IN ADVERSE FEELINGS
Skin reaction and blood clots; in back side rashes and blood clots on skin; in back side rashes and blood clots on skin; This spontaneous case was reported by a consumer and describes the occurrence of SKIN REACTION (Skin reaction and blood clots), CONTUSION (in back side rashes and blood clots on skin) and RASH (in back side rashes and blood clots on skin) in a 71-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 035C21A and 025C21A) for COVID-19 vaccination.     Concurrent medical conditions included Diabetes.   On 07-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 04-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Parenteral) dosage was changed to 1 dosage form. On 05-Jun-2021, the patient experienced SKIN REACTION (Skin reaction and blood clots), CONTUSION (in back side rashes and blood clots on skin) and RASH (in back side rashes and blood clots on skin). At the time of the report, SKIN REACTION (Skin reaction and blood clots), CONTUSION (in back side rashes and blood clots on skin) and RASH (in back side rashes and blood clots on skin) was resolving.            No concomitant medications were reported.   The reporter described the event as "in back side rashes and blood clots on skin." No treatment information was reported.
LETHARGIC; JOINT PAIN; This spontaneous report received from a patient via a company representative concerned a female of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On an unspecified date, the patient experienced lethargic, and joint pain. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of the lethargic and joint pain was not reported. This report was non-serious. This case, from the same reporter is linked to 20211130207.
Within about 5-6 hours of receiving the vaccine, the patient began to develop nausea, vomiting and diarrhea. He took OTC pepto bismol for relief of symptoms which lasted about 6-8 hours.  The next day patient was weak and stayed home from work. Fully recovered by day 2.
Information has been received from a physician concerning a female who was vaccinated with a dose of Gardasil.  Subsequently the patient's test results showed positive for HPV.  Unspecified medical attention was sought.  At the time of the report, the patient's outcome was unknown.  Additional information has been requested.
beginning the next morning, had pain in upper arm & into shoulder; could not lift arm; 8MAY had shooting pain underneath arm when lifting/moving arm; went away w/o any treatment;;
PT HAD PNEU SHOT THURSDAY 11/8/07 SITE STARTED TURNING RED FRIDAY 11/9/07.  THIS WAS PT'S 2ND PNEU SHOT. PT HAD STATED AT TIME OF INJ THAT SHE HAD NOT HAD ONE.  PT'S ARM RED,WARM(NO SWELLING) ON INSIDE OF ARM TO ELBOW ALL WEEKEND. BETTER MON BUT CLINIC CLOSED. PT CALLED TUES AND WAS ASKED TO COME TO CLINIC. ARM STILL PINK BUT PT DENIES ANY PAIN ADVISED NOT TO GET ANOTHER PNEU SHOT
FLU LIKE SYMPTOMS; BODY ACHES; DRY HEAVES; LETHARGY; SEVERE HEADACHES; SEVERE NAUSEA; LOW FEVER; This spontaneous report received from a consumer concerned a 53 year old female. The patient's height, and weight were not reported. The patient's past medical history included vertigo. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: Unknown) dose was not reported, administered on 02-APR-2021 for prophylactic vaccination. The batch number was not reported and has been requested. No concomitant medications were reported. On 03-APR-2021, the patient experienced flu like symptoms. On 03-APR-2021, the patient experienced body aches. On 03-APR-2021, the patient experienced dry heaves. On 03-APR-2021, the patient experienced lethargy. On 03-APR-2021, the patient experienced severe headaches. On 03-APR-2021, the patient experienced severe nausea. On 03-APR-2021, the patient experienced low fever. Laboratory data included: Body temperature (NR: not provided) 101 F. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient was recovering from body aches, had not recovered from severe nausea, and lethargy, and the outcome of flu like symptoms, low fever, severe headaches and dry heaves was not reported. This report was non-serious.
Headache, malaise, chills, muscle and joint aches, lethargy, and fever of 100°F.  Chills and fever began around 3:45am on 5/17. All symptoms began to resolve around 8pm. Full  resolution of symptoms achieved by 5:30am the next day (5/18).
FEVER FOR 8 TO 9 HOURS; This spontaneous report received from a patient concerned a 5 decade old male. The patient's weight was 163 pounds, and height was 175.26 centimeters. The patient's past medical history included: multiple surgeries (to remove benign nerve sheath tumors (schwannomas)) and mosaic schwannomatosis (also known as nerve fibromatosis type 3, presents only on the left side of the body, a condition of benign nerve sheath tumors called schwannomas that had nothing to do with respiratory), and other pre-existing medical conditions included: No family history of immune disorders. No concomitant medications or vaccine, any immunomodulatory drugs, steroids prior or after vaccination. No illness at the time of vaccination. No past history of similar event. No adverse event after any previous vaccination. No history of allergy to vaccine, drug or food. No pre-existing acute illness 30 days prior to vaccination. No history of hospitalization in the last 30 days prior to vaccination, with cause. Family history of hay fever. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 042A21A expiry: UNKNOWN) dose was not reported, administered on 09-APR-2021 for prophylactic vaccination. Age at time of vaccination 45 years old. No concomitant medications were reported. On 2021, the patient experienced fever for 8 to 9 hours. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from fever for 8 to 9 hours on 2021. This report was non-serious. This case, involving the same patient is linked to 20220627527.
Started mild cough, progressed to severe fits with regular difficulty breathing; Started mild cough, progressed to severe fits with regular difficulty breathing; "Flu-like" symptoms; This is a spontaneous report from a contactable consumer (patient). A 31-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number and expiration date were unknown) at the age of 31-years-old, via an unspecified route of administration in left arm on 19Apr2021 at 09:00 at 2nd dose, single for COVID-19 immunization. The patient's medical history, concurrent conditions and past drug history were reported as none. Prior to vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included venlafaxine hydrochloride (VENLAFAXINE) and methylphenidate. He did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: 59267100001) at the age of 31-years-old, via an unspecified route of administration in left arm on 22Mar2021 at 09:00 at 1st dose, single for COVID-19 immunization. The patient received the COVID-19 vaccine in a pharmacy/ drug store. As expected, 2-3 days post-vaccine, on Apr2021, the patient experienced flu-like symptoms. These dissipated but did not resolve completely. Then on 24Apr2021 (also reported as 5-6 days post-vaccine), he started to have mild cough which progressed to severe fits with regular difficulty breathing that has still not stopped 18 days later. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of events and included treatment with expectorant, cough suppressant, and antihistamine. The patient underwent lab test and procedures which included nasal swab: negative (SARS-COV-2 (COVID-19), QUALITATIVE, NAA) on 28Apr2021; nasal swab: negative (Bio-Rad SARS-CoV-2 ddPCR) on 30Apr2021; and nasal swab: negative (Binax NOW Coronavirus AG) on 30Apr2021. The outcome of the events was not recovered.   Information on the lot/batch number has been requested.
swollen lymph nodes in the area of the clavicle post 2nd dose; This is a spontaneous report from a contactable reporter reporting for a 33-year-old male patient who received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number: UNKNOWN) via an unspecified route of administration into the right arm on 15Feb2021 (at the age of 33-year-old) as single dose for COVID-19 immunization. The patient medical history and concomitant medications were not reported. Unknown if any allergies presented. On 15Mar2021, the patient experiencing swollen lymph nodes in the area of the clavicle post second dose. Prior to vaccination, the patient was not diagnosed with COVID-19 and unknown if tested post vaccination. No treatments received. It was unknown if the patient received any other vaccines within four weeks prior to the COVID vaccine. Unknown if since the vaccination, the patient had been tested for COVID-19 and also allergies to medications, food or other products. Reporter learned of the adverse event that reporter reported on behalf of someone on 26Mar2021, the same day it was reported. Outcome of the event was recovering.  No follow-up attempts are needed. No further information is expected.
terrible chills, couldn't get warm even with blankets, hat and gloves  - from 10 pm to about 11 next , morning  then the head ache which lasted until to next morning.  (Sunday)  Took tylonol several times.   On Monday better but kinda fuzzy and clumsy.
30 minutes after receiving the vaccine a red rash developed on my neck and it spread to my arms and back. I was taken to the ER and was given Benadryl and Prednisone to clear the rash
Two weeks after the first Pfizer injection (I have had three, including the booster), I developed bi-lateral arthritis pain in my hands. The pain ranked 8 on a scale of 1 to 10.  An x-ray 10 years ago detected arthritis in my hands; however, there was never pain. I visited a premier joint hospital in the US and the doctor told me I had osteoarthritis, which we knew. I specifically asked if the emergence of pain was in any way linked to the vaccintation. I was skeptical about the vaccine being the cause because the pain was bi-lateral. The doctor told me a) there was insufficient evidence from the CDC to conclude that this was related to the vaccine; b) she would not entirely eliminate the possibility; c) what was interesting was that the onset of the pain was immediately after the injection and d) the pain was bi-lateral.
Pt had some chest discomfort and muscle aches with first vaccine. We premedicated her with Motrin for second vaccine  Within 1 hr of second vaccine she started to have chills, body aches and vomiting.  We treated her with Zofran and pain relievers. She was getting better but 3 days later 1/24 started to have pressure feeling on her chest.  Concern for pericarditis and sent her to the ER.